Literature DB >> 7697694

Loperamide oxide in the treatment of acute diarrhea in adults.

A Dettmer.   

Abstract

We evaluated two doses of loperamide oxide (1 mg and 2 mg) and placebo in the treatment of acute diarrhea in 230 adult patients. Two tablets were taken initially and then one tablet after each watery, loose, or pasty stool to a maximum of eight tablets per day. The median time to complete relief was 27 hours 55 minutes for the 1-mg loperamide oxide group, 25 hours for the 2-mg loperamide oxide group, and 40 hours 35 minutes for the placebo group (P < 0.05). The investigator rated treatment as good or excellent for 78% of patients in each group treated with loperamide oxide and 62% of patients who received placebo. Constipation-like periods were no more common with loperamide oxide than with placebo. Adverse events were reported by four patients given loperamide oxide and three patients given placebo. The results demonstrate superior efficacy of loperamide oxide compared with placebo in the treatment of acute diarrhea in adults; because both doses of loperamide oxide are equally effective, the lower (1-mg) dose is preferred.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7697694

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

Review 1.  Diarrhoea in adults (acute).

Authors:  Thomas Gottlieb; Christopher Stewart Heather
Journal:  BMJ Clin Evid       Date:  2011-02-15

Review 2.  Diarrhoea in adults (acute).

Authors:  Guy de Bruyn
Journal:  BMJ Clin Evid       Date:  2008-03-04

3.  Potential of Loperamide Oxide in the Reduction of Ileostomy and Colostomy Output.

Authors:  P J Stevens; F Dunbar; P Briscoe
Journal:  Clin Drug Investig       Date:  1995-09       Impact factor: 2.859

4.  Efficacy of diosmectite (smecta) in the treatment of acute watery diarrhoea in adults: a multicentre, randomized, double-blind, placebo-controlled, parallel group study.

Authors:  Faouzi Khediri; Abdennebi Ilhem Mrad; Moussadek Azzouz; Hedi Doughi; Taoufik Najjar; Hélène Mathiex-Fortunet; Philippe Garnier; Antoine Cortot
Journal:  Gastroenterol Res Pract       Date:  2011-06-30       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.